FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the tumor originated. The approval marks a new paradigm in the development of cancer drugs that are “tissue agnostic.”


Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top